Cargando…
Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer
OBJECTIVE: Pt-Mal-LHRH is a newly synthesized chemotherapeutic agent that was designed to selectively target the luteinizing hormone-releasing hormone (LHRH) receptor expressed by triple negative breast cancer (TNBC). The aim of this study was to evaluate the therapeutic dosing, tumor reduction effi...
Autores principales: | Ndinguri, Margaret, Middleton, Lisa, Unrine, Jason, Lui, Shu, Rollins, Joseph, Nienaber, Emma, Spease, Cassidy, Williams, Aggie, Cormier, Lindsay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564129/ https://www.ncbi.nlm.nih.gov/pubmed/37816015 http://dx.doi.org/10.1371/journal.pone.0287151 |
Ejemplares similares
-
Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing
Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates
for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH
Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021) -
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014) -
LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer
por: Obayemi, J. D., et al.
Publicado: (2020) -
LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991) -
Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
por: Visapää, Harri
Publicado: (2017)